The present invention relates to a pharmaceutical combination preparation including an angiotensin-II receptor blocker and an HMG-CoA reductase inhibitor. More particularly, the present invention relates to a pharmaceutical combination preparation which is prepared by a process of granulating a mixture of an angiotensin-II receptor blocker or a pharmaceutically acceptable salt, an alkalinizing agent and a pharmaceutically acceptable additive, and then mixing the granules with the HMG-CoA reductase inhibitor.
